Clinical Trials Browser

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03751761 2024-02-28

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Phase 1/2 Completed

58 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05120622 2023-10-31

Rideau

Phase 1/2 Withdrawn

Genitourinary

Urinary Bladder Neoplasms

NCT03206073 2023-10-24

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Phase 1/2 Completed

34 enrolled 18 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT03522584 2023-06-12

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Terminated

6 enrolled 8 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03202758 2023-02-10

MEDITREME

Phase 1/2 Completed

57 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Phase 1/2 Completed

58 enrolled 24 charts

BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT02489448 2022-10-26

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Phase 1/2 Completed

68 enrolled 9 charts

Breast

Breast Neoplasms

NCT02311361 2021-04-20

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Phase 1/2 Completed

65 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01853618 2019-12-10

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

Phase 1/2 Completed

61 enrolled 18 charts

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

NCT00075192 2012-06-06

CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer

Phase 1/2 Completed

8 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

ABIMMUNE

ICRA

ADAPT-BLADDER

MOVIE

ICC

Durvalumab and Tremelimumab for Pediatric Malignancies

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

DUTRELASCO

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Rideau

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

MEDITREME

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer